These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 21933453)

  • 1. Bromodomains as therapeutic targets.
    Muller S; Filippakopoulos P; Knapp S
    Expert Rev Mol Med; 2011 Sep; 13():e29. PubMed ID: 21933453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.
    Hewings DS; Rooney TP; Jennings LE; Hay DA; Schofield CJ; Brennan PE; Knapp S; Conway SJ
    J Med Chem; 2012 Nov; 55(22):9393-413. PubMed ID: 22924434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Writers and readers of histone acetylation: structure, mechanism, and inhibition.
    Marmorstein R; Zhou MM
    Cold Spring Harb Perspect Biol; 2014 Jul; 6(7):a018762. PubMed ID: 24984779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule inhibitors of bromodomain-acetyl-lysine interactions.
    Brand M; Measures AR; Wilson BG; Cortopassi WA; Alexander R; Höss M; Hewings DS; Rooney TP; Paton RS; Conway SJ
    ACS Chem Biol; 2015 Jan; 10(1):22-39. PubMed ID: 25549280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disrupting Acetyl-lysine Interactions: Recent Advance in the Development of BET Inhibitors.
    Zhang F; Ma S
    Curr Drug Targets; 2018; 19(10):1148-1165. PubMed ID: 29189147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of human bromodomains in chromatin biology and gene transcription.
    Sanchez R; Zhou MM
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):659-65. PubMed ID: 19736624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A chemical toolbox for the study of bromodomains and epigenetic signaling.
    Wu Q; Heidenreich D; Zhou S; Ackloo S; Krämer A; Nakka K; Lima-Fernandes E; Deblois G; Duan S; Vellanki RN; Li F; Vedadi M; Dilworth J; Lupien M; Brennan PE; Arrowsmith CH; Müller S; Fedorov O; Filippakopoulos P; Knapp S
    Nat Commun; 2019 Apr; 10(1):1915. PubMed ID: 31015424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysine acetylation and cancer: A proteomics perspective.
    Gil J; Ramírez-Torres A; Encarnación-Guevara S
    J Proteomics; 2017 Jan; 150():297-309. PubMed ID: 27746255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone recognition and large-scale structural analysis of the human bromodomain family.
    Filippakopoulos P; Picaud S; Mangos M; Keates T; Lambert JP; Barsyte-Lovejoy D; Felletar I; Volkmer R; Müller S; Pawson T; Gingras AC; Arrowsmith CH; Knapp S
    Cell; 2012 Mar; 149(1):214-31. PubMed ID: 22464331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
    Romero FA; Taylor AM; Crawford TD; Tsui V; Côté A; Magnuson S
    J Med Chem; 2016 Feb; 59(4):1271-98. PubMed ID: 26572217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the Histone Acetylation Cycle in the Protozoan Model
    Wahab S; Saettone A; Nabeel-Shah S; Dannah N; Fillingham J
    Front Cell Dev Biol; 2020; 8():509. PubMed ID: 32695779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Combinatorial Histone Modifications on Acetyllysine Recognition by the ATAD2 and ATAD2B Bromodomains.
    Phillips M; Malone KL; Boyle BW; Montgomery C; Kressy IA; Joseph FM; Bright KM; Boyson SP; Chang S; Nix JC; Young NL; Jeffers V; Frietze S; Glass KC
    J Med Chem; 2024 May; 67(10):8186-8200. PubMed ID: 38733345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule BET inhibitors in clinical and preclinical development and their therapeutic potential.
    Yu L; Wang Z; Zhang Z; Ren X; Lu X; Ding K
    Curr Top Med Chem; 2015; 15(8):776-94. PubMed ID: 25732788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperative binding of two acetylation marks on a histone tail by a single bromodomain.
    Morinière J; Rousseaux S; Steuerwald U; Soler-López M; Curtet S; Vitte AL; Govin J; Gaucher J; Sadoul K; Hart DJ; Krijgsveld J; Khochbin S; Müller CW; Petosa C
    Nature; 2009 Oct; 461(7264):664-8. PubMed ID: 19794495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy.
    Wu D; Qiu Y; Jiao Y; Qiu Z; Liu D
    Front Oncol; 2020; 10():560487. PubMed ID: 33262941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromodomain Histone Readers and Cancer.
    Jain AK; Barton MC
    J Mol Biol; 2017 Jun; 429(13):2003-2010. PubMed ID: 27890782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging tools to investigate bromodomain functions.
    Kougnassoukou Tchara PE; Filippakopoulos P; Lambert JP
    Methods; 2020 Dec; 184():40-52. PubMed ID: 31726225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylases: salesmen and customers in the post-translational modification market.
    Brandl A; Heinzel T; Krämer OH
    Biol Cell; 2009 Apr; 101(4):193-205. PubMed ID: 19207105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecules as tools to study the chemical epigenetics of lysine acetylation.
    Schiedel M; Conway SJ
    Curr Opin Chem Biol; 2018 Aug; 45():166-178. PubMed ID: 29958150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.